| pubmed-article:8499153 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8499153 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:8499153 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:8499153 | lifeskim:mentions | umls-concept:C0280509 | lld:lifeskim |
| pubmed-article:8499153 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:8499153 | lifeskim:mentions | umls-concept:C0058809 | lld:lifeskim |
| pubmed-article:8499153 | lifeskim:mentions | umls-concept:C0133074 | lld:lifeskim |
| pubmed-article:8499153 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:8499153 | pubmed:dateCreated | 1993-6-29 | lld:pubmed |
| pubmed-article:8499153 | pubmed:abstractText | Brequinar (DUP 785, NSC 368390) is a 4-quinoline carboxylic acid derivative with broad spectrum antitumour activity in experimental models that acts as an antimetabolite by specific inhibition of de novo pyrimidine synthesis. We performed a phase I study of brequinar administered as a 10 min intravenous (i.v.) infusion for 5 consecutive days, every 4 weeks. 67 evaluable patients were entered in this study and a total of 130 courses were administered at doses ranging from 2 to 350 mg/m2. The dose-limiting toxicity was myelosuppression with predominant thrombocytopenia. Myelosuppression was dose-related and non-cumulative, with considerable interpatient variability depending on haematological risk factors. The maximum tolerated dose of brequinar was 210 mg/m2/day in poor risk patients whereas patients with good risk haematological profile tolerated higher doses (up to 350 mg/m2/day). Other non-limiting toxicities included nausea and vomiting, mucositis and skin reactions. Brequinar plasma pharmacokinetic profiles were biphasic with alpha half-life ranging from 0.1 to 0.7 h, and beta half-life ranging from 1.5 to 8.2 h. Increase in brequinar area under the plasma concentration versus time curves (AUC) was nonlinear. Day 5 brequinar pharmacokinetics obtained in 21 patients indicated a significant increase in AUC (47%) and half-life beta (133%) compared to day 1 pharmacokinetics in the same patient. Brequinar plasma AUC and the per cent change in platelet count at nadir were correlated (P < 0.001). Although no objective response was observed in this study, one minor response was noted in cervical lymph nodes of a Hodgkin's disease patient. | lld:pubmed |
| pubmed-article:8499153 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8499153 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8499153 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8499153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8499153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8499153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8499153 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8499153 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:GouyetteAA | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:ArmandJ PJP | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:DomengeCC | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:CardePP | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:FontaneTT | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:BarbuMM | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:de ForniMM | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:ChabotG GGG | lld:pubmed |
| pubmed-article:8499153 | pubmed:author | pubmed-author:RecondoGG | lld:pubmed |
| pubmed-article:8499153 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8499153 | pubmed:volume | 29A | lld:pubmed |
| pubmed-article:8499153 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8499153 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8499153 | pubmed:pagination | 983-8 | lld:pubmed |
| pubmed-article:8499153 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:meshHeading | pubmed-meshheading:8499153-... | lld:pubmed |
| pubmed-article:8499153 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8499153 | pubmed:articleTitle | Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients. | lld:pubmed |
| pubmed-article:8499153 | pubmed:affiliation | Institut Gustave-Roussy, Unité La Grange, Savigny Le Temple, France. | lld:pubmed |
| pubmed-article:8499153 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8499153 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8499153 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
